» Articles » PMID: 35270023

The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Mar 10
PMID 35270023
Authors
Affiliations
Soon will be listed here.
Abstract

Preeclampsia (PE) is characterised by high levels and activity of the transcription factor Nuclear Factor kappa B (NFĸB) in the maternal blood and placental cells. This factor is responsible for the regulation of over 400 genes known to influence processes related to inflammation, apoptosis and angiogenesis, and cellular responses to oxidative stress and hypoxia. Although high NFĸB activity induces hypoxia and inflammation, which are beneficial for the process of implantation, NFĸB level should be reduced in the later stages of physiological pregnancy to favour maternal immunosuppression and maintain gestation. It is believed that the downregulation of NFĸB activity by pharmacotherapy might be a promising way to treat preeclampsia. Interestingly, many of the drugs adopted for the prevention and treatment of preeclampsia have been found to regulate NFĸB activity. Despite this, further innovation is urgently needed to ensure treatment safety and efficacy. The present article summarizes the current state of knowledge about the drugs recommended by cardiology, obstetrics, and gynaecology societies for the prevention and treatment of preeclampsia with regard to their impact on the cellular regulation of NFĸB pathways.

Citing Articles

Clinical value of serum SIRT1 combined with uterine hemodynamics in predicting disease severity and fetal growth restriction in preeclampsia.

Ge T, Kong J J Med Biochem. 2024; 43(4):350-362.

PMID: 39139170 PMC: 11318065. DOI: 10.5937/jomb0-37645.


Metabolic theory of preeclampsia: implications for maternal cardiovascular health.

Manoharan M, Montes G, Acquarone M, Swan K, Pridjian G, Nogueira Alencar A Am J Physiol Heart Circ Physiol. 2024; 327(3):H582-H597.

PMID: 38968164 PMC: 11442029. DOI: 10.1152/ajpheart.00170.2024.


The NFκB Signaling Pathway Is Involved in the Pathophysiological Process of Preeclampsia.

Li Y, Zhu Q, He R, Du J, Qin X, Li Y Geburtshilfe Frauenheilkd. 2024; 84(4):334-345.

PMID: 38618576 PMC: 11006561. DOI: 10.1055/a-2273-6318.


New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.

Sakowicz A, Bralewska M, Rybak-Krzyszkowska M, Grzesiak M, Pietrucha T Int J Mol Sci. 2023; 24(15).

PMID: 37569476 PMC: 10418829. DOI: 10.3390/ijms241512100.


Clinical Value of Serum SIRT1 Combined with Uterine Hemodynamics in Predicting Disease Severity and Fetal Growth Restriction in Preeclampsia.

Ge T, Kong J Evid Based Complement Alternat Med. 2023; 2023:1744625.

PMID: 37064953 PMC: 10104738. DOI: 10.1155/2023/1744625.


References
1.
DAcquisto F, Iuvone T, Rombola L, Sautebin L, Di Rosa M, Carnuccio R . Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 1997; 418(1-2):175-8. DOI: 10.1016/s0014-5793(97)01377-x. View

2.
van der Merwe J, Hall D, Wright C, Schubert P, Grove D . Are early and late preeclampsia distinct subclasses of the disease--what does the placenta reveal?. Hypertens Pregnancy. 2010; 29(4):457-67. DOI: 10.3109/10641950903572282. View

3.
S K S S, Veeramohan , P H, Mathew T, S S, M C . Nifedipine inhibits hypoxia induced transvascular leakage through down regulation of NFkB. Respir Physiol Neurobiol. 2012; 183(1):26-34. DOI: 10.1016/j.resp.2012.05.016. View

4.
Mor G, Cardenas I, Abrahams V, Guller S . Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011; 1221:80-7. PMC: 3078586. DOI: 10.1111/j.1749-6632.2010.05938.x. View

5.
Bouguerne B, Belkheiri N, Bedos-Belval F, Vindis C, Uchida K, Duran H . Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties. Antioxid Redox Signal. 2010; 14(11):2093-106. DOI: 10.1089/ars.2010.3321. View